BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1476 related articles for article (PubMed ID: 18249467)

  • 81. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
    de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
    Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Nestin expression in cutaneous melanomas and melanocytic nevi.
    Brychtova S; Fiuraskova M; Hlobilková A; Brychta T; Hirnak J
    J Cutan Pathol; 2007 May; 34(5):370-5. PubMed ID: 17448190
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Apolipoprotein D expression in cutaneous malignant melanoma.
    Miranda E; Vizoso F; Martín A; Quintela I; Corte MD; Seguí ME; Ordiz I; Merino AM
    J Surg Oncol; 2003 Jun; 83(2):99-105. PubMed ID: 12772203
    [TBL] [Abstract][Full Text] [Related]  

  • 84. bcl-2 protein expression in melanocytic neoplasms of the skin.
    Ramsay JA; From L; Kahn HJ
    Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
    [TBL] [Abstract][Full Text] [Related]  

  • 85. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
    Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
    J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
    Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
    Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Common acquired melanocytic nevi, melanocytic dysplasia and malignant melanoma. A morphometric study.
    Santucci M; Urso C; Giannini A; Bondi R
    Appl Pathol; 1989; 7(2):111-5. PubMed ID: 2730799
    [TBL] [Abstract][Full Text] [Related]  

  • 88. In vivo confocal microscopy for detection and grading of dysplastic nevi: a pilot study.
    Pellacani G; Farnetani F; Gonzalez S; Longo C; Cesinaro AM; Casari A; Beretti F; Seidenari S; Gill M
    J Am Acad Dermatol; 2012 Mar; 66(3):e109-21. PubMed ID: 21742408
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cyclin D1 and D3 expression in melanocytic skin lesions.
    Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
    Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology.
    Rhodes AR; Mihm MC; Weinstock MA
    Mod Pathol; 1989 Jul; 2(4):306-19. PubMed ID: 2762287
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
    Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
    Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus.
    Schubert C; Parwaresch R; Rudolph P
    Virchows Arch; 2001 Feb; 438(2):166-72. PubMed ID: 11253119
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tumor progression in the human melanocytic system.
    Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
    Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
    Kuźbicki L; Gajo B; Chwirot BW
    Melanoma Res; 2006 Jun; 16(3):235-43. PubMed ID: 16718270
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma.
    Zhuang L; Scolyer RA; Lee CS; McCarthy SW; Cooper WA; Zhang XD; Thompson JF; Hersey P
    Histopathology; 2009 Mar; 54(4):462-70. PubMed ID: 19309398
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
    Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
    Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Clinicopathologic experience in a 100-bed hospital.
    Duray PH; Ernstoff MS
    Arch Dermatol; 1987 Jan; 123(1):80-4. PubMed ID: 3800426
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
    Perry BN; Cohen C; Govindarajan B; Cotsonis G; Arbiser JL
    Arch Dermatol; 2006 Aug; 142(8):1031-4. PubMed ID: 16924053
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The relationship between melanocytic nevi and malignant melanoma.
    Friedman RJ; Rigel DS; Heilman ER
    Dermatol Clin; 1988 Apr; 6(2):249-56. PubMed ID: 3378371
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
    Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
    Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 74.